New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|March 10, 2015
Trial Designs in Ovarian Cancer
Author(s)Jason D. Wright, MD
Jason D. Wright, MD, from Columbia University, discusses clinical trial designs in ovarian cancer.
Advertisement
Clinical Pearls
Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses clinical trial designs in ovarian cancer.
- Many patients with ovarian cancer receive a variety of off-label therapies. Nevertheless, overall survival has improved.
- The ovarian cancer community must weigh the pros and cons of a sound trial design with its application in the real world.
- Progression-free survival has its limitations but is probably the most reasonable trial endpoint.
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
3
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
4
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
5